{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:48:27Z","timestamp":1791395307881,"version":"4.3.3"},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jcjd.2019.01.001","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T22:44:56Z","timestamp":1547160296000},"page":"4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertensive Patients With Type 2 Diabetes Mellitus"],"prefix":"10.1016","volume":"44","author":[{"given":"Tomoyuki","family":"Kawada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2019.01.001_bib1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jcjd.2017.11.006","article-title":"Angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers for the treatment of hypertension in adults with type 2 diabetes: Why we favour angiotensin receptor blockers","volume":"42","author":"Mavrakanas","year":"2018","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2019.01.001_bib2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jash.2015.05.004","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension: Are they equivalent?","volume":"9","author":"Kaplan","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jcjd.2019.01.001_bib3","doi-asserted-by":"crossref","first-page":"k4209","DOI":"10.1136\/bmj.k4209","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: Population based cohort study","volume":"363","author":"Hicks","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jcjd.2019.01.001_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jaip.2017.03.017","article-title":"Cardiovascular and diabetic medications that cause bradykinin-mediated angioedema","volume":"5","author":"Hudey","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jcjd.2019.01.001_bib5","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1161\/HYPERTENSIONAHA.113.02767","article-title":"Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition","volume":"63","author":"Devin","year":"2014","journal-title":"Hypertension"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267118310104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267118310104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:34:28Z","timestamp":1761492868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267118310104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1499267118310104"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2019.01.001","relation":{},"ISSN":["1499-2671"],"issn-type":[{"value":"1499-2671","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors for the Treatment of Hypertensive Patients With Type 2 Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2019.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2017.11.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Canadian Diabetes Association","name":"copyright","label":"Copyright"}]}}